Peptide policy published in the Federal Register (enforcement discretion, not approval), Q3 results on 9 Nov

BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax, exactly the list from the July advisory committee. Hims had said it would launch wellness peptides once the policy opened up, and CEO Dudum called the news encouraging. But this is a decision not to enforce, not an approval, and it has three structural limits. (1) It covers only 503A pharmacies and licensed physicians. Telehealth prescribing with delivery from Hims's own pharmacy fits within the framework, but the products cannot be made in bulk like ordinary goods. (2) It does not bind the states. State pharmacy boards do the actual regulating, and some states may not follow. (3) It can be withdrawn at any time, there is no draft formal rule, FDA reviewers objected, and apart from BPC-157 the other five peptides have no human safety studies. The market is worth $2.0-3.3 billion, a supplement rather than a second GLP-1. The structure resembles the compounded semaglutide windfall during the shortage: the policy risk has not gone, it has simply moved to a new category. The FTC case has a hearing on 7 Jan, so advertising will be watched more closely. At Q3 results on 9 Nov, watch for the peptide launch date, the first products, pricing and whether peptide subscribers are disclosed separately.